La vendita allo scoperto per Blueprint Medicines dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Blueprint Medicines. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Blueprint Medicines (NASDAQ:BPMC) Azioni, Report sulle vendite allo scoperto

Blueprint Medicines

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines Corp

JMP Securities analyst Reni Benjamin reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Market Outperform and maintains $125 price target.

News

Price Target

Reiteration

Analyst Ratings

BPMC

JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $125 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $135 price target.

HC Wainwright & Co. Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $135 price target.

Needham Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target

JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), a biotech company&nbsp;focused on modulating immune mast cells.
In 2023, the FDA approved Blueprint Medicines&#8217; Ayvakit (avapritinib) as the first, only treatment for&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32537616/blueprint-medicines-earns-higher-price-targets-post-fda-approval-analysts-optimisti" rel="noreferrer noopener">indolent systemic mastocytosis</a> (ISM).
In the third quarter of 2024, Ayvakit reported net product revenues of&nbsp;$128.2 million, including&nbsp;$113.1 million&nbsp;in the U.S. and&nbsp;$15.1 million&nbsp;ex-U.S., representing 136% growth year over year.
Blueprint Medicines anticipates approximately&nbsp;$475 million&nbsp;to&nbsp;$480 million&nbsp;in global Ayvakit net product revenues in 2024, an increase from &nbsp;$435 million&nbsp;to&nbsp;$450 million <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41620913/blueprint-medicines-reports-third-quarter-2024-results-and-raises-ayvakit-ayvakyt-avapritinib-full" rel="noreferrer noopener">in the previous range</a>.
This updated guidance is based on continued growth in patients on therapy, continued favorability in compliance and other performance factors, and stronger-than-expected performance outside of the U.S.
JP Morgan initiates with an Overweight rating and a price target of $126, <a target="_blank" href="https://www.benzinga.com/quote/BPMC/analyst-ratings" rel="noreferrer noopener">an upside of almost 30%</a>.
The analyst&#8217;s positive outlook is based on Ayvakit&#8217;s strong launch and growing success. Early adoption has been solid, and while Ayvakit is currently approved for three uses, most attention is on its performance in ISM.
Key factors support the belief that Ayvakit could surpass $2 billion in peak sales. In less than four years on the market, annual revenue already exceeds $475 million, highlighting its significant growth potential.
&#8220;Heading into 1Q25, we also believe BPMC could be seen as an attractive target for strategic partnerships, which could boost shares,&#8221; JP Morgan writes.
With Ayvakit&#8217;s launch being a major focus for Blueprint Medicines, the analyst says that investors are largely overlooking its wildtype KIT (&#8216;808) program.
This program has the potential to open the door to larger markets, including treatments for urticaria and asthma. We look forward to more details on Blueprint Medicines&#8217; plans during their scientific seminar later today and expect Phase 1 trial data in early 2025.
Price Action: BPMC stock is up 0.25% at $97.12&nbsp;at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41978891/immuteps-lead-cancer-drug-shows-promising-2-year-survival-data-in-lung-cancer-trial" target="_blank" rel="noreferrer noopener">Immutep&#8217;s Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial</a></li>
</ul>

Analyst Color

Biotech

Health Care

Initiation

Trading Ideas

General

Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst

Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $128.0, along with a high estimate of $151.00 and a low estimate of $88.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 7.58%. 
<img src="https://www.benzinga.com/files/images/story/2024/1731603642_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Blueprint Medicines's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$126.00</td>
<td>-</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$151.00</td>
<td>$153.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$135.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$133.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>David Dai</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$88.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Blueprint Medicines. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Blueprint Medicines's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Blueprint Medicines's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>Discovering Blueprint Medicines: A Closer Look</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
<h3>Financial Milestones: Blueprint Medicines's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Blueprint Medicines displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 126.61%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Blueprint Medicines's net margin is impressive, surpassing industry averages. With a net margin of -43.9%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Blueprint Medicines's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -17.77%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Blueprint Medicines's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -4.68%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Blueprint Medicines's debt-to-equity ratio surpasses industry norms, standing at 1.51. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Blueprint Medicines Analyst Ratings

JP Morgan analyst Brian Cheng initiates coverage on Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Overweight rating and announces Price Target of $126.

JP Morgan Initiates Coverage On Blueprint Medicines with Overweight Rating, Announces Price Target of $126

Wells Fargo analyst Derek Archila maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Overweight and lowers the price target from $153 to $151.

Wells Fargo Maintains Overweight on Blueprint Medicines, Lowers Price Target to $151

Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and raises the price target from $133 to $135.

Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $135

WIIM

Blueprint Medicines shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 net product revenue guidance. Needham reiterated a Buy rating on the stock.

Needham analyst Ami Fadia reiterates Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and maintains $133 price target.

Needham Reiterates Buy on Blueprint Medicines, Maintains $133 Price Target

This updated guidance is based on continued growth in patients on therapy, continued favorability in compliance and other performance factors, and stronger than expected performance outside of the U.S. The company continues to expect that full-year operating expenses and cash burn will decline in 2024 as compared to 2023, and that its existing cash, cash equivalents and investments, together with anticipated product revenues, will enable the company to maintain a durable capital position to achieve a self-sustainable financial profile.

Earnings

Guidance

Blueprint Medicines Expects 2024 Ayvakit Net Product Revenues Of $475M-$480M Compared To Prior Guidance Of $435M-$450M

Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) reported quarterly losses of $(0.89) per share which beat the analyst consensus estimate of $(0.96) by 7.29 percent. This is a 59.55 percent increase over losses of $(2.20) per share from the same period last year. The company reported quarterly sales of $128.18 million which beat the analyst consensus estimate of $127.03 million by 0.91 percent. This is a 126.61 percent increase over sales of $56.57 million the same period last year.

Blueprint Medicines Q3 2024 GAAP EPS $(0.89) Beats $(0.96) Estimate, Sales $128.18M Beat $127.03M Estimate

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $120.17, a high estimate of $138.00, and a low estimate of $88.00. Witnessing a positive shift, the current average has risen by 4.13% from the previous average price target of $115.40.
<img src="https://www.benzinga.com/files/images/story/2024/1729782012_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Blueprint Medicines. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Dai</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$133.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Michael Schmitz</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$138.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$127.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Blueprint Medicines. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Blueprint Medicines compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Blueprint Medicines's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Blueprint Medicines's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BPMC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Blueprint Medicines analyst ratings.</a>
<h2>All You Need to Know About Blueprint Medicines</h2>
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
<h3>Blueprint Medicines: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Blueprint Medicines's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 139.98%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Blueprint Medicines's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -36.19% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Blueprint Medicines's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -15.85%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -4.46%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.48, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Blueprint Medicines

UBS analyst David Dai initiates coverage on Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Neutral rating and announces Price Target of $88.

UBS Initiates Coverage On Blueprint Medicines with Neutral Rating, Announces Price Target of $88

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$29.00</td>
<td>$46.5K</td>
<td>31.3K</td>
<td>38.7K</td>
</tr>
<tr>
<td>IBRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$4.00</td>
<td>$97.6K</td>
<td>250</td>
<td>10.0K</td>
</tr>
<tr>
<td>VRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$25.00</td>
<td>$43.7K</td>
<td>1.4K</td>
<td>1.1K</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$17.50</td>
<td>$38.0K</td>
<td>3.2K</td>
<td>954</td>
</tr>
<tr>
<td>NBIX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$150.00</td>
<td>$45.6K</td>
<td>782</td>
<td>321</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$67.50</td>
<td>$29.9K</td>
<td>768</td>
<td>104</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/23/24</td>
<td>$126.00</td>
<td>$56.4K</td>
<td>8</td>
<td>86</td>
</tr>
<tr>
<td>BPMC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$105.00</td>
<td>$42.3K</td>
<td>417</td>
<td>58</td>
</tr>
<tr>
<td>EXAS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$50.00</td>
<td>$67.5K</td>
<td>488</td>
<td>16</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with neutral sentiment. It expires in 3 day(s) on August 16, 2024. Parties traded 1500 contract(s) at a $29.00 strike. The total cost received by the writing party (or parties) was $46.5K, with a price of $31.0 per contract. There were 31318 open contracts at this strike prior to today, and today 38747 contract(s) were bought and sold. 
• For IBRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>), we notice a call option trade that happens to be bearish, expiring in 66 day(s) on October 18, 2024. This event was a transfer of 2169 contract(s) at a $4.00 strike. The total cost received by the writing party (or parties) was $97.6K, with a price of $45.0 per contract. There were 250 open contracts at this strike prior to today, and today 10038 contract(s) were bought and sold. 
• Regarding VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we observe a call option sweep with bearish sentiment. It expires in 3 day(s) on August 16, 2024. Parties traded 199 contract(s) at a $25.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $43.7K, with a price of $220.0 per contract. There were 1424 open contracts at this strike prior to today, and today 1129 contract(s) were bought and sold. 
• Regarding SAVA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>), we observe a put option sweep with bearish sentiment. It expires in 157 day(s) on January 17, 2025. Parties traded 40 contract(s) at a $17.50 strike. This particular put needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $38.0K, with a price of $951.0 per contract. There were 3205 open contracts at this strike prior to today, and today 954 contract(s) were bought and sold. 
• Regarding NBIX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>), we observe a call option trade with bullish sentiment. It expires in 38 day(s) on September 20, 2024. Parties traded 30 contract(s) at a $150.00 strike. The total cost received by the writing party (or parties) was $45.6K, with a price of $1520.0 per contract. There were 782 open contracts at this strike prior to today, and today 321 contract(s) were bought and sold. 
• Regarding EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we observe a call option trade with bullish sentiment. It expires in 94 day(s) on November 15, 2024. Parties traded 65 contract(s) at a $67.50 strike. The total cost received by the writing party (or parties) was $29.9K, with a price of $460.0 per contract. There were 768 open contracts at this strike prior to today, and today 104 contract(s) were bought and sold. 
• Regarding MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we observe a put option trade with bearish sentiment. It expires in 10 day(s) on August 23, 2024. Parties traded 47 contract(s) at a $126.00 strike. The total cost received by the writing party (or parties) was $56.4K, with a price of $1202.0 per contract. There were 8 open contracts at this strike prior to today, and today 86 contract(s) were bought and sold. 
• Regarding BPMC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), we observe a put option trade with bearish sentiment. It expires in 66 day(s) on October 18, 2024. Parties traded 29 contract(s) at a $105.00 strike. The total cost received by the writing party (or parties) was $42.3K, with a price of $1460.0 per contract. There were 417 open contracts at this strike prior to today, and today 58 contract(s) were bought and sold. 
• For EXAS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), we notice a call option trade that happens to be neutral, expiring in 157 day(s) on January 17, 2025. This event was a transfer of 50 contract(s) at a $50.00 strike. The total cost received by the writing party (or parties) was $67.5K, with a price of $1350.0 per contract. There were 488 open contracts at this strike prior to today, and today 16 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

EXAS

IBRX

NBIX

SAVA

VRNA

9 Health Care Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$35.00</td>
<td>$127.1K</td>
<td>48.0K</td>
<td>3.3K</td>
</tr>
<tr>
<td>NTRA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$105.00</td>
<td>$36.6K</td>
<td>113</td>
<td>1.7K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$450.00</td>
<td>$30.7K</td>
<td>575</td>
<td>519</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/20/24</td>
<td>$57.50</td>
<td>$28.0K</td>
<td>3.2K</td>
<td>322</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$85.00</td>
<td>$29.7K</td>
<td>945</td>
<td>153</td>
</tr>
<tr>
<td>QDEL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$60.00</td>
<td>$29.0K</td>
<td>0</td>
<td>146</td>
</tr>
<tr>
<td>HROW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$12.00</td>
<td>$66.0K</td>
<td>339</td>
<td>100</td>
</tr>
<tr>
<td>BPMC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$95.00</td>
<td>$30.6K</td>
<td>1</td>
<td>80</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$900.00</td>
<td>$76.0K</td>
<td>308</td>
<td>61</td>
</tr>
<tr>
<td>DHR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$120.00</td>
<td>$75.1K</td>
<td>83</td>
<td>55</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option trade with bullish sentiment. It expires in 162 day(s) on January 17, 2025. Parties traded 3100 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $127.1K, with a price of $41.0 per contract. There were 48092 open contracts at this strike prior to today, and today 3303 contract(s) were bought and sold. 
• For NTRA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), we notice a call option sweep that happens to be bearish, expiring in 8 day(s) on August 16, 2024. This event was a transfer of 39 contract(s) at a $105.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $36.6K, with a price of $940.0 per contract. There were 113 open contracts at this strike prior to today, and today 1738 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 134 day(s) on December 20, 2024. This event was a transfer of 58 contract(s) at a $450.00 strike. This particular put needed to be split into 20 different trades to become filled. The total cost received by the writing party (or parties) was $30.7K, with a price of $530.0 per contract. There were 575 open contracts at this strike prior to today, and today 519 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option trade with bearish sentiment. It expires in 43 day(s) on September 20, 2024. Parties traded 100 contract(s) at a $57.50 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $280.0 per contract. There were 3203 open contracts at this strike prior to today, and today 322 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a put option sweep with neutral sentiment. It expires in 8 day(s) on August 16, 2024. Parties traded 100 contract(s) at a $85.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $29.7K, with a price of $298.0 per contract. There were 945 open contracts at this strike prior to today, and today 153 contract(s) were bought and sold. 
• For QDEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QDEL#NASDAQ">QDEL</a>), we notice a call option sweep that happens to be bullish, expiring in 225 day(s) on March 21, 2025. This event was a transfer of 121 contract(s) at a $60.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $29.0K, with a price of $240.0 per contract. There were 0 open contracts at this strike prior to today, and today 146 contract(s) were bought and sold. 
• For HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we notice a call option trade that happens to be bearish, expiring in 71 day(s) on October 18, 2024. This event was a transfer of 30 contract(s) at a $12.00 strike. The total cost received by the writing party (or parties) was $66.0K, with a price of $2200.0 per contract. There were 339 open contracts at this strike prior to today, and today 100 contract(s) were bought and sold. 
• For BPMC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>), we notice a call option trade that happens to be bearish, expiring in 162 day(s) on January 17, 2025. This event was a transfer of 30 contract(s) at a $95.00 strike. The total cost received by the writing party (or parties) was $30.6K, with a price of $1020.0 per contract. There were 1 open contracts at this strike prior to today, and today 80 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be bullish, expiring in 99 day(s) on November 15, 2024. This event was a transfer of 20 contract(s) at a $900.00 strike. The total cost received by the writing party (or parties) was $76.0K, with a price of $3800.0 per contract. There were 308 open contracts at this strike prior to today, and today 61 contract(s) were bought and sold. 
• Regarding DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we observe a call option sweep with bearish sentiment. It expires in 134 day(s) on December 20, 2024. Parties traded 5 contract(s) at a $120.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $75.1K, with a price of $15020.0 per contract. There were 83 open contracts at this strike prior to today, and today 55 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HROW

MRNA

NTRA

QDEL

10 Health Care Stocks Whale Activity In Today's Session

Needham analyst Ami Fadia maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and raises the price target from $130 to $133.

Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133

Guggenheim analyst Michael Schmitz maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Buy and raises the price target from $130 to $138.

Guggenheim Maintains Buy on Blueprint Medicines, Raises Price Target to $138

Baird analyst Joel Beatty maintains Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) with a Outperform and raises the price target from $112 to $127.

Baird Maintains Outperform on Blueprint Medicines, Raises Price Target to $127

JPMorgan initiated coverage of Blueprint Medicines (BPMC) with an Overweight rating and $126 price target Blueprint is a biotech company focused on...

Blueprint Medicines initiated with an Overweight at JPMorgan

Blueprint Medicines (BPMC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ulz ...

Blueprint Medicines: Hold Rating Amidst Future Research Potential and Clinical Uncertainties

Analyst Ami Fadia of Needham maintained a Buy rating on Blueprint Medicines (BPMC – Research Report), retaining the price target of $135.00. Ami Fa...

Blueprint Medicines' Promising Pipeline Developments Support Buy Rating

H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on BPMC stock, giving a Buy rating today. Andrew Fein's rating is based on ...

Blueprint Medicines: Innovative Approaches and Pipeline Potential Drive Buy Rating

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Blueprint Medicines (BPMC – Research Report). The company's shares ...

TD Cowen Reaffirms Their Buy Rating on Blueprint Medicines (BPMC)

Blueprint Medicines' Growth With AYVAKIT And Next-Gen Oncology Drugs

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Steris (STE – Research Report), Benitec Biopharma (B...

Analysts Are Bullish on These Healthcare Stocks: Steris (STE), Benitec Biopharma (BNTC)

Finding Winners In Biotech, Probably The Riskiest Sector

Vertex leads J.P. Morgan's top biotech picks list for 2025

Wall Street Lunch: Holiday-Shortened Week Starts Positively

ABBV

ALRM

AZNCF

BACRP

BNTC

EWTX

IMVT

LPTX

MSTR

PTCT

REGCO

REGCP

RIGL

ROIV

STRO

SWTX

TARS

TVTX

VERA

VRTX

VYGR

XENE

Press Releases

Blueprint Medicines Announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT®/AYVAKYT® (avapritinib)

Investors Have the Opportunity to Join the Following Securities Fraud Investigations: Avangrid, Inc. (AGR), Squarespace, Inc. (SQSP), and Blueprint Medicines Corporation (BPMC)

Comments

Blueprint Medicines

Vendite allo scoperto

Blueprint Medicines (NASDAQ:BPMC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO